ALAS2: Potential Drug Target Or Biomarker for Urinary Tract Infections and Other Diseases

Target Name: ALAS2

NCBI ID: G212

ALAS2

ALAS2: Potential Drug Target Or Biomarker for Urinary Tract Infections and Other Diseases

ALAS2 (5'-aminolevulinate synthase 2) is a gene that encodes a protein known as ALAS2, which is involved in the production of aminolevulinic acid, a metabolite that is derived from the amino acid leucine. Aminolevulinic acid is a key precursor for the development of certain bacteria, including those that cause urinary tract infections and other types of infections. ALAS2 plays a crucial role in the production of these bacteria, and is therefore a potential drug target or biomarker for a variety of diseases.

ALAS2 is a member of the Superfamily A of the Planar blindfolded proteins (PBP), which are a family of proteins that are characterized by their ability to self- Assemble into highly ordered structures that lack classical Z-layers. PBP proteins are involved in a wide range of cellular processes, including cell signaling, cytoskeletal organization, and chromatin structure. ALAS2 is specifically involved in the production of a type of PBP protein known as P2, which is a key regulator of the bacterial cell wall.

In addition to its role in cell signaling and cytoskeletal organization, ALAS2 is also involved in the regulation of bacterial growth and development. In recent years, studies have shown that ALAS2 plays a crucial role in the production of aminolevulinic acid, which is a key precursor for the development of certain bacteria. In fact, ALAS2 is specifically required for the growth and development of bacteria that are commonly found in the gut, such as those that cause urinary tract infections.

The ability of ALAS2 to produce aminolevulinic acid also makes it a potential drug target or biomarker for a variety of diseases. For example, urinary tract infections (UTIs) are a common cause of medical emergency, and are often treated with antibiotics that are able to kill bacteria that are resistant to traditional antibiotics. However, the development of antibiotic-resistant bacteria is a growing concern, and there is a need for new approaches to treat UTIs. ALAS2 may be a potential drug target or biomarker for the development of new antibiotics that are able to treat UTIs.

In addition to its potential as a drug target or biomarker, ALAS2 may also be a useful tool for the study of bacterial infections and other types of disease. For example, the ability of ALAS2 to produce aminolevulinic acid has been used to study the effects of different antibiotics on the growth and behavior of different types of bacteria. This can provide valuable insights into the mechanisms of bacterial infections and the development of new treatments.

Overall, ALAS2 is a protein that is involved in a wide range of cellular processes, including cell signaling, cytoskeletal organization, and the regulation of bacterial growth and development. The ability of ALAS2 to produce aminolevulinic acid also makes it a potential drug target or biomarker for a variety of diseases, including urinary tract infections. Further research is needed to fully understand the role of ALAS2 in these and other processes, and to develop new treatments for a variety of diseases.

Protein Name: 5'-aminolevulinate Synthase 2

Functions: Catalyzes the pyridoxal 5'-phosphate (PLP)-dependent condensation of succinyl-CoA and glycine to form aminolevulinic acid (ALA), with CoA and CO2 as by-products (PubMed:14643893, PubMed:32499479, PubMed:21252495, PubMed:21653323, PubMed:21309041). Contributes significantly to heme formation during erythropoiesis (PubMed:2050125)

The "ALAS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ALAS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets